MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/hjh.0000000000004075

Медицинская библиотека · Journal of hypertension · 2025

Efficacy and safety of sacubitril/valsartan in Afro-descendant patients with resistant hypertension: a randomized controlled trial.

Bitar Yasmin de Souza Lima, Durães André Rodrigues, de Macedo Cristiano Ricardo Bastos, Aras Marcela Gordilho, Santos Levi Cardozo, de Abreu Rogério Smith Freire, Dos Santos Enilson Carmo Barbosa, Bocchi Edimar, da Silva Wallace Andre Pedro, Aras Junior Roque

СтатьяРандомизированное исследованиеКлиническое исследование III фазыПеревод в очереди

Аннотация

BACKGROUND

Sacubitril/valsartan (Sac-Val) has demonstrated blood pressure (BP)-lowering effects, but its role in resistant hypertension remains unclear. This study evaluated the efficacy and safety of Sac-Val compared to optimized angiotensin II receptor blocker (ARB) or angiotensin-converting enzyme inhibitor (ACEI) therapy in Brazilian patients with resistant hypertension, predominantly Afro-descendant.

METHODS

In this phase III, 8-week, single-center, randomized trial, 80 adults with resistant hypertension were assigned to Sac-Val (titrated to 200 mg with an optional increase to 400 mg if BP remained >140/90 mmHg) or standard therapy (ARB/ACEI combined with other antihypertensive agents). The primary endpoint was the proportion of patients achieving BP control (<140/90 mmHg). The co-primary endpoints included mean reductions in mean sitting SBP (msSBP), mean sitting DBP (msDBP), and mean sitting pulse pressure (msPP) at week 8. Secondary outcomes assessed dose-dependent BP reduction.

RESULTS

BP control was achieved in 94.9% of patients in the Sac-Val group versus 69.2% in the control group ( P  = 0.03). Sac-Val significantly reduced msPP (-6.05 mmHg, P  = 0.008) and showed a trend toward greater msSBP reduction ( P  = 0.06). The 400 mg dose resulted in the greatest BP reduction, particularly for msPP ( P  = 0.034). No deaths were reported.

CONCLUSION

Sac-Val was more effective than standard therapy in achieving BP control and reducing BP in resistant hypertension, with a dose-dependent trend favoring the 400 mg regimen. These findings support Sac-Val as a potential treatment alternative for high-risk Afro-descendant patients.

Для цитирования: Bitar Yasmin de Souza Lima, Durães André Rodrigues, de Macedo Cristiano Ricardo Bastos, Aras Marcela Gordilho, Santos Levi Cardozo, de Abreu Rogério Smith Freire, Dos Santos Enilson Carmo Barbosa, Bocchi Edimar, da Silva Wallace Andre Pedro, Aras Junior Roque. Efficacy and safety of sacubitril/valsartan in Afro-descendant patients with resistant hypertension: a randomized controlled trial.. Journal of hypertension. 2025. DOI: 10.1097/hjh.0000000000004075.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.